Imagine Pharma is a leading biotechnology company dedicated to the research and development of transformative treatments that revolutionize patients' lives. Our primary focus is on the development of the groundbreaking IMG-1 polypeptide through three distinct platforms, each containing first-in-class programs. Our pipeline comprises a range of innovative oral delivery therapeutics and regenerative medicine programs, addressing various disease states in large underserved markets.

The programs include PT-1 EPO, PT-2 Octreotide, and PT-3 GLP-1 Agonist for exceptional treatment outcomes. Furthermore, we offer cutting-edge solutions for skin grafting, diabetic wounds, and burns through our top-of-the-line Top-1 Skin Graft, Top-2 Diabetic Wound, and Top-3 Burns programs. Our commitment to improving patient lives extends to our AIPCs T1 Diabetes Autologous Transplant programs, which aim to transform the lives of those with type 1 diabetes.

Driven by a world-class team of scientists, clinicians, and executive leaders, we have established a state-of-the-art laboratory in Pittsburgh's economic opportunity zone. This facility enables us to pioneer proof-of-concept innovations using advanced techniques, fostering creativity and collaboration. Experience the future of medicine with Imagine Pharma – where groundbreaking solutions meet patient-centered care.

Connect with us to learn more about our programs and explore new possibilities in healthcare